KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) R&D In Process (2021 - 2026)

Bristol Myers Squibb has reported R&D In Process over the past 6 years, most recently at $94.0 million for Q1 2026.

  • Quarterly R&D In Process fell 50.0% to $94.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.6 billion through Mar 2026, up 492.81% year-over-year, with the annual reading at $3.7 billion for FY2025, 72.18% down from the prior year.
  • R&D In Process was $94.0 million for Q1 2026 at Bristol Myers Squibb, down from $1.4 billion in the prior quarter.
  • Over five years, R&D In Process peaked at $12.9 billion in Q1 2024 and troughed at $30.0 million in Q3 2022.
  • The 5-year median for R&D In Process is $188.0 million (2025), against an average of $1.1 billion.
  • Year-over-year, R&D In Process soared 17165.33% in 2024 and then crashed 98.55% in 2025.
  • A 5-year view of R&D In Process shows it stood at $52.0 million in 2022, then skyrocketed by 1053.85% to $600.0 million in 2023, then plummeted by 95.0% to $30.0 million in 2024, then soared by 4543.33% to $1.4 billion in 2025, then plummeted by 93.25% to $94.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's R&D In Process are $94.0 million (Q1 2026), $1.4 billion (Q4 2025), and $633.0 million (Q3 2025).